Figure 5
From: Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway
Mechanism underlying the therapeutic effects of metformin on olanzapine-induced NAFLD. Olanzapine induces the expression of LXRα in the liver and subsequently upregulates PCSK9 expression, which in turn affects hepatic lipid metabolism-associated genes (such as FAS, SCD1, SCAD and PPARα), thereby accelerating lipid accumulation. Conversely, metformin reduces the expression of LXRα in the liver and subsequently downregulates PCSK9, which in turn reduces the expression of FAS and SCD1, thereby ameliorating olanzapine-induced NAFLD.
